Eli Lilly: single-dose vials of Zepbound available
(CercleFinance.com) - Eli Lilly has announced that 2.
5 mg and 5 mg single-dose vials of Zepbound are available on a self-pay basis in the US, for patients with a prescription on label, significantly increasing the product's supply in response to strong demand.
The pharmaceutical company says that the price of the single-dose vials is 50% or more below the list price of all other incretin (GLP-1)-based drugs for the treatment of obesity.
This new option should help millions of obese adults gain access to the drug, including those not eligible for the Zepbound savings card program, not covered by their employer or who have to pay for it themselves as not covered by insurance.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
5 mg and 5 mg single-dose vials of Zepbound are available on a self-pay basis in the US, for patients with a prescription on label, significantly increasing the product's supply in response to strong demand.
The pharmaceutical company says that the price of the single-dose vials is 50% or more below the list price of all other incretin (GLP-1)-based drugs for the treatment of obesity.
This new option should help millions of obese adults gain access to the drug, including those not eligible for the Zepbound savings card program, not covered by their employer or who have to pay for it themselves as not covered by insurance.
Copyright (c) 2024 CercleFinance.com. All rights reserved.